Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project is a randomized controlled trial of electroconvulsive therapy (ECT) compared to treatment as usual (TAU) in the treatment of treatment resistant depression (TRD) in bipolar disorder. The purpose of the trial is to document the effect size, relative effect size and adverse effects of ECT in this condition. A specific purpose is to gain more knowledge about the effect on cognitive function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression

NCT05463562

Depressive Disorder Bipolar Disorder

UNKNOWN

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression

NCT06661616

Major Depressive Disorder (MDD) Bipolar Disorder Depression

COMPLETED

HD-tDCS for Adolescent Bipolar Depression Targeting S1

NCT07246044

Adolescent Bipolar Depression tDCS +2 more

RECRUITING NA

Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.

NCT01748708

Depressive Disorder

WITHDRAWN NA

Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression

NCT00069407

Depression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project is a randomized controlled trial of electroconvulsive therapy (ECT) compared to treatment as usual (TAU) in the treatment of treatment resistant depression (TRD) in bipolar disorder. The purpose of the trial is to document the effect size, relative effect size and adverse effects of ECT in this condition. A specific purpose is to gain more knowledge about the effect on cognitive function.

In a national collaboration project the investigators will compare the antidepressant and cognitive effects of ECT with the effects of a drug treatment in use for this condition; a treatment algorithm combining antidepressants, mood stabilizer and antipsychotic drugs. The investigators will use a neuropsychological test battery to disclose possible ECT induced changes in cognitive function, and investigate any long-lasting changes.

In addition, several studies have implemented inflammatory processes in the pathogenesis of depression; inflammatory processes will be examined as a function of changes in clinical status and of treatment modality.

The study is a national collaboration, using the Bipolar Research And Innovation Network- BRAIN, and all the patients are included in the BRAIN-study. The study is funded by Helse Vest RHF, Regional research network on mood disorders (MoodNet) and Norwegian hospitals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Electroconvulsive therapy

Group Type EXPERIMENTAL

Electroconvulsive therapy

Intervention Type PROCEDURE

Electroconvulsive therapy

2

Treatment as usual

Group Type ACTIVE_COMPARATOR

Treatment as usual

Intervention Type OTHER

Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electroconvulsive therapy

Intervention Type PROCEDURE

Treatment as usual

Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ECT indicated
* Diagnosis of DSM-IV-TR of Bipolar I or Bipolar II disorder as verified by the semi-structured diagnostic interviews SCID or MINI plus.
* Severity: meet DSM-IV-TR criteria of depressive episode, MADRS of 25 or above.
* Treatment resistance
* None response to two trials (during lifetime) with mood stabilizer with proven efficacy in bipolar depression (lithium, lamotrigine, quetiapine, olanzapine) and /or antidepressants.
* A trial is defined as at least 6 weeks in adequate or tolerated dose as reported by the patient, or patients that have been unable to comply with 6 weeks trials of mood stabilizer or an antidepressant.
* Less than 50% reduction in MADRS values or still meet DSM -IV-TR criteria of depressive episode
* Inpatients the first week after start of treatment condition
* The patient are to be treated by the psychiatrist at the hospital for the whole duration of the study (6 weeks)
* Age ≥ 18
* Patient competent to give informed consent according to the judgement of the clinician
* Written informed consent
* Patient fluent in Norwegian language

Exclusion Criteria

* Earlier ECT nonresponse
* ECT within the last six months
* More than four failed adequate medication trials in the current episode
* Rapid cycling bipolar disorder (e.g.4 or more episodes per year)
* Use of medication or substances (such as pethidine, alcohol, drugs) incompatible with drug medication or ECT. Such medication must be stopped a least 5 half-lives before inclusion in the study.
* Current use of all other psychotropic medication 5 t1/2 before inclusion and during the study period with the exception of the following:
* The use of alimemazine (max dose 30 mg daily), chlorpromazine (max dose 25 mg x 2 daily) and chlorprotixen (max dose 20 mg x 2) is allowed. The use of mianserin (max dose 10 mg daily) is allowed. Such medication has to been discontinued at least 2 days prior neuropsychological assessment. Medication related to the ECT procedure is allowed.
* Inability to comply with study protocol
* Unstable serious medical conditions, including clinically relevant laboratory abnormalities
* Conditions that affect neuropsychological assessment such as Parkinson's Disease, Multiple sclerosis, stroke, alcohol and substance abuse or dependence (according to SCID or DSM-IV-TR)
* Pregnancy or lactation
* Fertile women without adequate contraception (Adequate contraception includes: abstinence, oral contraceptives, intrauterine devices, barrier method)
* YMRS of 20 or more
* Patient at high suicidal risk according to clinicians' judgment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No